Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 30

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 30
---
arrants

The following is a brief summary
of the Series E Warrants, December 2023 Private Placement Pre-Funded Warrants and the December 2023 Underwriter Warrants, issued in connection
with the December 2023 private placements and December 2023 public offering, and is subject in all respects to the provisions contained
in the applicable warrants, which are filed as exhibits to Registration Statement on Form F-1. Unless otherwise stated, references to
warrants in this subsection include the Series E Warrants, the December 2023 Private Placement Pre-Funded Warrants, and the December 2023
Underwriter Warrants.

Exercisability.The
warrants became exercisable on December 21, 2023. The Series E Warrants and December 2023 Underwriter Warrants expire five years and three
years, respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants are exercisable at any time
and do not expire. The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within
two trading days following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

| 22 |

Cashless Exercise. If, at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of the securities
underlying the Series E Warrants under the Securities Act is not then effective or available and an exemption from registration under
the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to
be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise
(either in whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E Warrants.

At the time a holder exercises
its December 2023 Private Placement Pre-Funded Warrants, in lieu of making the cash payment otherwise contemplated to be made to us upon
such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part) the net number of Depositary Shares determined according to a formula set forth in the December 2023 Private Placement Pre-Funded
Warrants.

Exercise Price.The
exercise price of each Series E Warrant, December 2023 Underwriter Warrant and December 2023 Private Placement Pre-Funded Warrant is $55